Philips reaches compliance agreement with FDA over ventilator recall

The agreement sets out the improvements that Philips needs to make at its Respironics plants in order to be able to sell new respiratory devices in the U.S. again.

"We are fully committed to complying with the consent decree, which is an important step and provides a clear path forward," Chief Executive Roy Jakobs said in a statement.

The decree is being finalised and will be submitted to the relevant U.S. court for approval.

Philips recalled millions of breathing devices and ventilators used to treat sleep apnea in 2021 because foam used to dampen noise from the devices can degrade and become toxic, carrying potential cancer risks.

The operation knocked about 70 per cent off Philips' market value, as investors feared large litigation bills.

Philips said the agreement did not change its expectations of reaching mid-single-digit comparable sales growth and a low-teens profit margin, in adjusted EBITA, in 2025, with a free cash flow of 1.4 billion to 1.6 billion euros.

Due to the provision, Philips core profit in the fourth quarter remained roughly stable at 653 million euros, while comparable sales fell 1 per cent .

Analysts in a company-compiled poll on average had predicted adjusted EBITA would rise to 672 million euros, from 651 million euros a year before, with comparable sales growth of 2.6 per cent .

Philips said it expected to deliver 3-5 per cent comparable sales growth in 2024, with an adjusted EBITA margin of 11-11.5 per cent . ($1 = 0.9226 euros)